Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the 1st patient in clinical trial of its suspension formulation of corticosteroid triamcinolone acetonide, Zuprata, for the treatment of diabetic macular edema.
The Alpharetta, Ga.-based company’s Hulk Phase I/II trial is an open-label, multi-center study designed to evaluate the safety and efficacy Zuprata administered in the suprachoroidal space along with intravitreal aflibercept and as an independent therapy in patients with diabetic macular edema. The trial is slated to enroll 20 patients with equal participation in both arms. Anatomical and functional data as well as safety information will be collected at monthly visits over a 6-month period, according to Clearside.
Get the full story at our sister site, Drug Delivery Business News
The post Clearside Biomedical launches trial for Zuprata appeared first on MassDevice.
from MassDevice http://ift.tt/2fcUExF
Cap comentari:
Publica un comentari a l'entrada